Science Explorer Back to mapMap
Discussion
Company · Sherbrooke · Canada

Immune Biosolutions (Canada)

ibiosolutions.comROR OpenAlex
Research works
0
fractional, all time
Citations
4
9.5 per fractional work
Top-10% rate
4.8%
all institutions 10.0%
Open access
100%
world 40%
International
12%
world 18%
Immune Biosolutions (Canada)

Not ranked overall: Immune Biosolutions (Canada) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Immune Biosolutions (Canada) work in?

In all years, 75% of research at Immune Biosolutions (Canada) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (75%), Biochemistry, Genetics and Molecular Biology (25%).

Health Sciences: 0 fractional works · 75.0% of its workMedicine: 0 fractional works · 75.0% of its workLife Sciences: 0 fractional works · 25.0% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 25.0% of its workALL ITS WORKImmuneBiosolutions…0fractional works, all years
Life Sciences25%Health Sciences75%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 2 fields, with their numbers
    1. Medicine075.0%
    1. Biochemistry, Genetics and Molecular Biology025.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Immune Biosolutions (Canada)?

The most cited paper from Immune Biosolutions (Canada) is "Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial" (Bruno Maranda, Sébastien M. Labbé, Magali Lurquin et al., 2023), with 17 citations. Next come "Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors" (1) and "A Randomized, Double-Blind, Dose-Ascending, Placebo-Controlled Phase 1-2 Trial of Inhaled IBIO123: A Monoclonal Antibodies Cocktail Treatment for Mild-To Moderate COVID-19 Illness" (1).

Most cited papers
#PaperReleasedCitations
1 Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial Bruno Maranda, Sébastien M. Labbé, Magali Lurquin et al. · The Lancet Infectious Diseases Open access 21 Aug 2023 17
2 Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors Marie-Édith Nepveu-Traversy, Malihe Hassanzadeh, Laurent Bruneau‐Cossette et al. · Nature Communications Open access 12 Dec 2025 1
3 A Randomized, Double-Blind, Dose-Ascending, Placebo-Controlled Phase 1-2 Trial of Inhaled IBIO123: A Monoclonal Antibodies Cocktail Treatment for Mild-To Moderate COVID-19 Illness Bruno Maranda, Sébastien M. Labbé, Magali Lurquin et al. · SSRN Electronic Journal PreprintOpen access 2023 1
4 Safety and Efficacy of Inhaled IBIO123 for Severe COVID-19: A Randomised, Double-Blind, Dose-Ascending, Placebo-Controlled, Phase 1/2 Trial Sébastien M. Labbé, Bruno Maranda, Magali Lurquin et al. · SSRN Electronic Journal PreprintOpen access 2023 0
All 4 most cited papers, with filters and sorting

Which research topics does Immune Biosolutions (Canada) publish most on?

By volume in 2022-now: Monoclonal and Polyclonal Antibodies Research, Long-Term Effects of COVID-19, COVID-19 Clinical Research Studies and Receptor Mechanisms and Signaling.

Monoclonal and Polyclonal Antibodies Research: 0 fractional worksLong-Term Effects of COVID-19: 0 fractional worksCOVID-19 Clinical Research Studies: 0 fractional worksReceptor Mechanisms and Signaling: 0 fractional worksChemical Synthesis and Analysis: 0 fractional worksSARS-CoV-2 and COVID-19 Research: 0 fractional works
Radiology, Nuclear Medicine and ImagingNeurologyInfectious DiseasesMolecular Biology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  2. 2 Long-Term Effects of COVID-19 Neurology 0 works
  3. 3 COVID-19 Clinical Research Studies Infectious Diseases 0 works
  4. 4 Receptor Mechanisms and Signaling Molecular Biology 0 works
  5. 5 Chemical Synthesis and Analysis Molecular Biology 0 works
  6. 6 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available100.0%

World: 40% of research is openly available.

with international co-authors11.8%domestic only88.2%

World: 18% is written across borders.

Other research institutions in Sherbrooke

All research institutions in Sherbrooke

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Immune Biosolutions (Canada). Posts are plain text and can be reported.